Published in Vaccine Weekly, July 9th, 2008
CureVac — which specializes in the therapeutic application of messenger RNA, a biomolecule that transfers genetic information from nuclear DNA to cellular protein production machinery — is developing a stabilized mRNA-derived vaccine for treatment of prostate cancer.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly